Lipid Nanoparticle Preparation via Ionizable Lipid Mixing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of nucleic acids to cells is hindered by their instability and low cell permeability, and existing lipid-containing nanoparticles lack improvements in safety, efficacy, and specificity.
Innovation Solution
A method of preparing empty and loaded lipid nanoparticles (LNPs) by mixing an ionizable lipid with a buffering agent, followed by the incorporation of nucleic acids, which includes a specific composition of PEG lipid and structural lipids, to enhance stability and intracellular delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If nucleic acids are delivered directly to cells, then the delivery process is simple, but the nucleic acids exhibit instability and low cell permeability
Solution Approach 1:
The patent uses composite lipid materials including ionizable lipids, PEG lipids, and structural lipids to form LNPs that encapsulate nucleic acids. This composite approach combines the protective and delivery capabilities of different lipid types to overcome the instability and low permeability of bare nucleic acids while maintaining a feasible manufacturing process.
Solution Approach 2:
The patent employs lipid bilayer membranes as flexible shells to encapsulate nucleic acids. These lipid films provide protection while allowing cellular uptake, resolving the contradiction between simplicity and effectiveness by creating a structure that is both manufacturable and biologically effective.
2Reliability
If conventional lipid-containing nanoparticles are used, then some delivery capability is achieved, but safety, efficacy, and specificity improvements are lacking
Solution Approach 1:
The patent optimizes critical parameters including PEG lipid concentration (0.1-5 mol%), ionizable lipid pKa (6.0-7.5), and lipid ratio compositions to enhance safety and reduce immunogenicity. By systematically adjusting these parameters, the invention achieves improved therapeutic index while maintaining delivery efficacy.
Solution Approach 2:
The patent employs biodegradable lipid components that break down after delivering their cargo, reducing long-term toxicity and immunogenicity. These temporary delivery vehicles provide their function and then degrade, improving safety profiles compared to conventional persistent nanoparticles.
3Stability of the object's composition
If PEG lipid content is increased to improve LNP stability, then physical stability improves, but immunogenicity may increase
Solution Approach 1:
The patent identifies and optimizes the PEG lipid concentration parameter within a specific range (0.1-5 mol%) to achieve the optimal balance between physical stability and immunogenicity. This parameter optimization resolves the contradiction by finding the sweet spot where stability is sufficient without excessive immunogenic response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in more stable and effective intracellular delivery of nucleic acids, with improved physical and biological properties, including increased nucleic acid expression and reduced immunogenicity, allowing for point-of-care formulation and storage optimization.
Implementation Method 1
a mixing step, comprising mixing an ionizable lipid with a first buffering agent, thereby forming the empty LNP
Data Source
AI summary
The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and LNP formulations produced by using such methods. The present disclosure further provides therapeutic and diagnostic uses related to the produced LNP formulations.